<DOC>
	<DOCNO>NCT00417079</DOCNO>
	<brief_summary>This randomize , open-label , multi-center study compare safety efficacy XRP6258 plus prednisone mitoxantrone plus prednisone treatment hormone refractory metastatic prostate cancer previously treat Taxotere®-containing regimen . The primary objective overall survival . Secondary objective include progression free survival , overall response rate , prostate-specific antigen ( PSA ) response/progression , pain response/progression , overall safety , pharmacokinetics . Patients treated disease progression , death , unacceptable toxicity , maximum 10 cycle . Patients long-term follow-up maximum 2 year .</brief_summary>
	<brief_title>XRP6258 Plus Prednisone Compared Mitoxantrone Plus Prednisone Hormone Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Inclusion Criteria 1 . Histologically cytologically confirm adenocarcinoma prostate refractory hormone therapy previously treat Taxotere®containing regimen . 2 . Documented progression disease ( demonstrate least one visceral soft tissue metastatic lesion , include new lesion ) . Patients nonmeasurable disease must document rise prostatespecific antigen ( PSA ) level appearance new lesion . 3 . Surgical hormoneinduced castration 4 . Life expectancy &gt; 2 month 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Exclusion criterion 1 . Previous treatment mitoxantrone 2 . Previous treatment &lt; 225 mg/m^2 cumulative dose Taxotere ( docetaxel ) 3 . Prior radiotherapy ≥ 40 % bone marrow 4 . Surgery , radiation , chemotherapy , anticancer therapy within 4 week prior enrollment study 5 . Other prior malignancy , except adequately treat superficial basal cell skin cancer , cancer patient diseasefree less 5 year 6 . Known brain leptomeningeal involvement 7 . Other concurrent serious illness medical condition 8 . Inadequate organ function evidence unacceptable laboratory result The investigator evaluate whether reason patient may participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Prostate</keyword>
</DOC>